NCT02085135View on ClinicalTrials.gov

A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Major Depressive Disorder
Interventions
DRUG

ALKS 5461

Sublingual tablet taken once daily

Trial Locations (9)

10305

Alkermes Investigational Site, Staten Island

18104

Alkermes Investigational Site, Allentown

30308

Alkermes Investigational Site, Atlanta

32256

Alkermes Investigational Site, Jacksonville

32806

Alkermes Investigational Site, Orlando

45417

Alkermes Investigational Site, Dayton

63304

Alkermes Investigational Site, Saint Charles

98007

Alkermes Investigational Site, Bellevue

Unknown

Alkermes Investigational Site, Halifax

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY